Literature DB >> 10783133

Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide.

M K Tulić1, J L Wale, P G Holt, P D Sly.   

Abstract

The potential role of respiratory infections in altering the development of atopy and asthma is complex. Infections have been suggested to be effective in preventing the induction of T-helper 2-polarized allergen-specific immunity in early life, but also to exacerbate asthma in older, sensitized individuals. The mechanism(s) underlying these effects are poorly defined. The aim of this work was to determine the influence of lipopolysaccharide (LPS) exposure on the development of sensitization to allergen and the response to allergen challenge in vivo. Piebald-Virol-Glaxo rats were exposed to a single aerosol of LPS 1 d before or 1, 2, 4, 6, 8, or 10 d after sensitization with ovalbumin (OVA). On Day 11 animals were exposed to 1% OVA and responses to allergen were measured 24 h later, monitoring inflammatory cell influx and microvascular leakage into bronchoalveolar lavage (BAL) fluid as well as pulmonary responses to methacholine using the forced oscillation technique. Histologic analysis was included to complement the BAL results. Single aerosol exposure to LPS 1 d before and up to 4 d after intraperitoneal injection of OVA protected against the development of OVA-specific immunoglobulin (Ig) E. LPS exposure 6, 8, or 10 d after sensitization further exacerbated the OVA-induced cellular influx, resulting in neutrophilia and increased Evans Blue dye leakage with no effect on serum IgE levels. In addition, LPS abolished the OVA-induced hyperresponsiveness in sensitized animals when given 18 h after OVA challenge. This study demonstrates that exposure to LPS can modify the development of allergic inflammation in vivo by two independent mechanisms. Exposure early in the sensitization process, up to Day 6 after exposure to allergen, prevented allergen sensitization. Exposure to LPS after allergen challenge in sensitized animals abolished the hyperresponsiveness and modified the inflammatory cell influx characteristic of late-phase response to allergen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10783133     DOI: 10.1165/ajrcmb.22.5.3710

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  44 in total

Review 1.  Does environmental endotoxin exposure prevent asthma?

Authors:  J Douwes; N Pearce; D Heederik
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

Review 2.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Attenuated Salmonella typhimurium reduces ovalbumin-induced airway inflammation and T-helper type 2 responses in mice.

Authors:  C-J Wu; L-C Chen; M-L Kuo
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Comparison of the Effect of Ribosomal Immunotherapy on Plasma Levels of Total IgE and Cytokines IL-4, IL-5, IL-12 and IFNgamma in Adult Atopic and Non-Atopic Patients during the Pollen Season.

Authors:  J Bystron; Z Hermanová; J Szotkovská; L Heller; D Pazderová
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

5.  Effect of Ribosomal Immunotherapy on the Clinical Condition and Plasma Levels of Cytokines IL-4, IL-5, IL-12 and IFNgamma and Total IgE in Patients with Seasonal Allergy during the Pollen Season.

Authors:  J Bystron; Z Hermanová; J Szotkovská; L Heller; D Pazderová
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 6.  Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma.

Authors:  Pieter Bogaert; Kurt G Tournoy; Thomas Naessens; Johan Grooten
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

7.  Reproducibility of a novel model of murine asthma-like pulmonary inflammation.

Authors:  L McKinley; J Kim; G L Bolgos; J Siddiqui; D G Remick
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

8.  Inhibition of Th2 adaptive immune responses and pulmonary inflammation by leukocyte Ig-like receptor B4 on dendritic cells.

Authors:  Rebecca G Breslow; Jayanti J Rao; Wei Xing; David I Hong; Nora A Barrett; Howard R Katz
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

9.  Maternal smoking in pregnancy: do the effects on innate (toll-like receptor) function have implications for subsequent allergic disease?

Authors:  Susan L Prescott; Paul S Noakes
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

10.  Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations.

Authors:  Po-Chang Chiang; Yiding Hu; Jason D Blom; David C Thompson
Journal:  Nanoscale Res Lett       Date:  2010-04-10       Impact factor: 4.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.